Find Reports

Select Report Type

Learn More about Reports

Reimbursement Review

Displaying 1426 - 1429 of 1429

Health Technology Review

Filter

Project Sub Line

Last Updated

Min

Max

Items per page

Export to CSV

Displaying 601 - 602 of 602

Horizon Scan

Filter

Project Sub Line

Last Updated

Min

Max

Items per page

Export to CSV

Displaying 101 - 110 of 110

Projects in Progress

Filter

Project Sub Line

Last Updated

Min

Max

Items per page

Export to CSV

Displaying 26 - 26 of 26

View All Reports

Filter

Project Sub Line

Last Updated

Min

Max

Items per page

Export to CSV

Displaying 1476 - 1500 of 2141

Please scroll or swipe to view the full content.

Title	Files	Last Updated Sort ascending	Project Line	Project Sub Line	Status	Project Number
Reimbursement of Newer Drugs for Type 2 Diabetes in Canada: An Environmental ScanOpens in new tab		Feb 26, 2019	Health Technology Review	Environmental Scan	Completed	ES0337-000
CADTH Pharmaceutical Reviews Update — Issue 5Opens in new tab		Feb 20, 2019	Reimbursement Review	Pharmaceutical Review Update
ertugliflozinOpens in new tab	Recommendation and Reasons Opens in new tab Clinical Report Opens in new tab Pharmacoeconomic Report Opens in new tab Patient Input Summary Opens in new tab	Feb 8, 2019	Reimbursement Review		Complete	SR0565-000
ertugliflozin and metformin Opens in new tab	Recommendation and Reasons Opens in new tab New Combination Product Submission Opens in new tab	Feb 7, 2019	Reimbursement Review		Complete	SR0566-000
sucroferric oxyhydroxide Opens in new tab	Recommendation and Reasons Opens in new tab Clinical Report Opens in new tab Pharmacoeconomic Report Opens in new tab Patient Group Input Submissions Opens in new tab	Feb 1, 2019	Reimbursement Review		Complete	SR0571-000
lixisenatide + insulin glargineOpens in new tab	Recommendation and Reasons Opens in new tab Clinical Report Opens in new tab Pharmacoeconomic Report Opens in new tab Patient Group Input Submissions Opens in new tab	Jan 30, 2019	Reimbursement Review		Complete	SR0564-000
fluticasone propionate Opens in new tab	Recommendation and Reasons Opens in new tab Clinical Report Opens in new tab Pharmacoeconomic Report Opens in new tab Patient Group Input Submissions Opens in new tab	Jan 21, 2019	Reimbursement Review		Complete	SR0539-000
Tagrisso for Non-Small Cell Lung Cancer (first line) – DetailsOpens in new tab	Provincial Funding Summary Opens in new tab Osimertinib (Tagrisso) NSCLC (first line) – pERC Final Recommendation Opens in new tab Osimertinib (Tagrisso) NSCLC (first line) - Final Clinical Guidance Report Opens in new tab Osimertinib (Tagrisso) NSCLC (first line) - Final Economic Guidance Report Opens in new tab Osimertinib (Tagrisso) NSCLC (first line) - pERC Initial Recommendation Opens in new tab Osimertinib (Tagrisso) NSCLC (first line) – PAG Feedback on Initial Recommendation Opens in new tab Osimertinib (Tagrisso) NSCLC (first line) – Submitter Feedback on Initial Recommendation Opens in new tab Osimertinib (Tagrisso) NSCLC (first line) – Patient Feedback on Initial Recommendation Opens in new tab Osimertinib (Tagrisso) NSCLC (first line) – Clinician Feedback on Initial Recommendation Opens in new tab Osimertinib (Tagrisso) NSCLC (first line) – Patient COI Declarations Opens in new tab Osimertinib (Tagrisso) NSCLC (first line) – Clinician COI Declarations Opens in new tab	Jan 21, 2019	Reimbursement Review		Complete	PC0137-000
benralizumabOpens in new tab	Recommendation and Reasons Opens in new tab Clinical Report Opens in new tab Pharmacoeconomic Report Opens in new tab Patient Group Input Submissions Opens in new tab	Jan 16, 2019	Reimbursement Review		Complete	SR0561-000
Tisagenlecleucel for Acute Lymphoblastic Leukemia and Diffuse Large B-cell Lymphoma: RecommendationsOpens in new tab		Jan 15, 2019	Health Technology Review	Optimal Use	Completed	OP0538-000 / CT0001
Tisagenlecleucel (Kymriah) for Pediatric Acute Lymphoblastic Leukemia and Diffuse Large B-Cell LymphomaOpens in new tab	Tisagenlecleucel for B-Cell Acute Lymphoblastic Leukemia and Diffuse Large B-Cell Lymphoma — Project Protocol, Clinical Section Opens in new tab Tisagenlecleucel for B-Cell Acute Lymphoblastic Leukemia and Diffuse Large B-Cell Lymphoma — Project Protocol, Implementation and Ethics Section Opens in new tab Tisagenlecleucel for Acute Lymphoblastic Leukemia and Diffuse Large B-Cell Lymphoma -Patient Input Submissions Opens in new tab	Jan 15, 2019	Health Technology Review	Optimal Use	Completed	OP0538-000 / CT0001
nitisinoneOpens in new tab	Recommendations and Reasons Opens in new tab Clinical Report Opens in new tab Pharmacoeconomic Report Opens in new tab Patient Group Input Submissions Opens in new tab	Jan 14, 2019	Reimbursement Review		Complete	SR0538-000
Levodopa / carbidopa (Drug Plan Submission)Opens in new tab	Recommendation and Reasons Opens in new tab Clinical Report Opens in new tab Pharmacoeconomic Report Opens in new tab Patient Group Input Submissions Opens in new tab Implementation Advice Opens in new tab	Jan 14, 2019	Reimbursement Review		Complete	SR0557-000
Mvasi for Metastatic Colorectal Cancer / Non-Small Cell Lung Cancer Biosimilar – DetailsOpens in new tab	Provincial Funding Summary Opens in new tab Bevacizumab (Mvasi) mCRC NSCLC Biosimilar - Summary Dossier Opens in new tab	Jan 14, 2019	Reimbursement Review		Complete	PC0158-000
Detection and Diagnosis of Sepsis in Rural and Remote Areas: An Environmental ScanOpens in new tab		Jan 9, 2019	Health Technology Review	Environmental Scan	Completed	ES0327-000
RivaroxabanOpens in new tab	Recommendation and Reasons Opens in new tab Clinical Report Opens in new tab Pharmacoeconomic Report Opens in new tab	Jan 3, 2019	Reimbursement Review		Complete	SR0569-000
ozenoxacinOpens in new tab	Recommendation and Reasons Opens in new tab Clinical Report Opens in new tab Pharmacoeconomic Report Opens in new tab Patient Group Input Submissions Opens in new tab	Dec 21, 2018	Reimbursement Review		Complete	SR0553-000
bictegravir/emtricitabine/tenofovir alafenamideOpens in new tab	Recommendations and Reasons Opens in new tab Clinical Report Opens in new tab Pharmacoeconomic Report Opens in new tab Patient Group Input Submissions Opens in new tab	Dec 21, 2018	Reimbursement Review		Complete	SR0567-000
Tapentadol HydrochlorideOpens in new tab	Recommendation and Reasons Opens in new tab Clinical Report Opens in new tab Pharmacoeconomic Report Opens in new tab Patient Group Input Submissions Opens in new tab	Dec 21, 2018	Reimbursement Review		Complete	SR0563-000
dexamethasone Opens in new tab	Recommendation and Reasons Opens in new tab Clinical Report Opens in new tab Pharmacoeconomic Report Opens in new tab Patient Group Input Submissions Opens in new tab	Dec 21, 2018	Reimbursement Review		Complete	SR0535-000
sebelipase alfaOpens in new tab	Recommendation and Reasons Opens in new tab Clinical Report Opens in new tab Pharmacoeconomic Report Opens in new tab Patient Group Input Submissions Opens in new tab Implementation Advice Opens in new tab	Dec 21, 2018	Reimbursement Review		Complete	SR0544-000
Opdivo for Hepatocellular Carcinoma – DetailsOpens in new tab	Provincial Funding Summary Opens in new tab Nivolumab (Opdivo) HCC – pERC Final Recommendation Opens in new tab Nivolumab (Opdivo) HCC – Final Clinical Guidance Report Opens in new tab Nivolumab (Opdivo) HCC – Final Economic Guidance Report Opens in new tab Nivolumab (Opdivo) HCC – pERC Initial Recommendation Opens in new tab Nivolumab (Opdivo) HCC – PAG Feedback on Initial Recommendation Opens in new tab Nivolumab (Opdivo) HCC – Manufacturer Feedback on Initial Recommendation Opens in new tab Nivolumab (Opdivo) HCC – Clinician Feedback on Initial Recommendation Opens in new tab Nivolumab (Opdivo) HCC – Patient COI Declarations Opens in new tab Nivolumab (Opdivo) HCC – Clinician COI Declarations Opens in new tab	Dec 14, 2018	Reimbursement Review		Complete	PC0134-000
Perjeta-Herceptin Combo Pack for Early Breast Cancer – DetailsOpens in new tab	Provincial Funding Summary Opens in new tab Pertuzumab-Trastuzumab (Perjeta-Herceptin Combo Pack) EBC – pERC Final Recommendation Opens in new tab Pertuzumab-Trastuzumab (Perjeta-Herceptin Combo Pack) EBC – Final Clinical Guidance Report Opens in new tab Pertuzumab-Trastuzumab (Perjeta-Herceptin Combo Pack) EBC – Final Economic Guidance Report Opens in new tab Pertuzumab-Trastuzumab (Perjeta-Herceptin Combo Pack) EBC - pERC Initial Recommendation Opens in new tab Pertuzumab-Trastuzumab (Perjeta-Herceptin Combo Pack) EBC – PAG Feedback on Initial Recommendation Opens in new tab Pertuzumab-Trastuzumab (Perjeta-Herceptin Combo Pack) EBC – Manufacturer Feedback on Initial Recommendation Opens in new tab Pertuzumab-Trastuzumab (Perjeta-Herceptin Combo Pack) EBC – Patient Feedback on Initial Recommendation Opens in new tab Pertuzumab-Trastuzumab (Perjeta-Herceptin Combo Pack) EBC – Clinician Feedback on Initial Recommendation Opens in new tab Pertuzumab-Trastuzumab (Perjeta-Herceptin Combo Pack) EBC – Patient COI Declarations Opens in new tab Pertuzumab-Trastuzumab (Perjeta-Herceptin Combo Pack) EBC – Clinician COI Declarations Opens in new tab	Dec 14, 2018	Reimbursement Review		Complete	PC0127-000
CADTH Pharmaceutical Reviews Update — Issue 4Opens in new tab		Dec 13, 2018	Reimbursement Review	Pharmaceutical Review Update
lumacaftor/ivacaftorOpens in new tab	Recommendation and Reasons Opens in new tab Clinical Report Opens in new tab Pharmacoeconomic Report Opens in new tab Patient Group Input Submissions Opens in new tab	Nov 19, 2018	Reimbursement Review		Complete	SR0559-000

Provisional Funding Algorithm

Displaying 76 - 81 of 81